These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 21764277

  • 1. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
    Price D, Gray A, Gale R, Asukai Y, Mungapen L, Lloyd A, Peters L, Neidhardt K, Gantner T.
    Respir Med; 2011 Nov; 105(11):1635-47. PubMed ID: 21764277
    [Abstract] [Full Text] [Related]

  • 2. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
    Price D, Asukai Y, Ananthapavan J, Malcolm B, Radwan A, Keyzor I.
    Appl Health Econ Health Policy; 2013 Jun; 11(3):259-74. PubMed ID: 23529714
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, Ställberg B.
    Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 5. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
    Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D.
    Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
    [Abstract] [Full Text] [Related]

  • 6. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
    Vogelmeier C, Magnussen H, LaForce C, Owen R, Kramer B.
    Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
    [Abstract] [Full Text] [Related]

  • 7. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 8. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
    Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B, INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators.
    Eur Respir J; 2011 Feb 15; 37(2):273-9. PubMed ID: 20693243
    [Abstract] [Full Text] [Related]

  • 9. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML, Chapman KR, Dahl R, Frith P, Devouassoux G, Fritscher C, Cameron R, Shoaib M, Lawrence D, Young D, McBryan D, INVIGORATE investigators.
    Lancet Respir Med; 2013 Sep 15; 1(7):524-33. PubMed ID: 24461613
    [Abstract] [Full Text] [Related]

  • 10. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.
    Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C, INSIST study group.
    Respir Med; 2011 May 15; 105(5):719-26. PubMed ID: 21367594
    [Abstract] [Full Text] [Related]

  • 11. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.
    Respir Med; 2008 Jul 15; 102(7):1033-44. PubMed ID: 18479895
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
    Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ.
    J Med Econ; 2011 Jul 15; 14(6):805-15. PubMed ID: 21992217
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
    Chan MC, Tan EC, Yang MC.
    Int J Chron Obstruct Pulmon Dis; 2018 Jul 15; 13():1079-1088. PubMed ID: 29670344
    [Abstract] [Full Text] [Related]

  • 14. Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
    Hoogendoorn M, Kappelhoff BS, Overbeek JA, Wouters EF, Rutten-van Mölken MP.
    Neth J Med; 2012 Oct 15; 70(8):357-64. PubMed ID: 23065983
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.
    Najafzadeh M, Marra CA, Sadatsafavi M, Aaron SD, Sullivan SD, Vandemheen KL, Jones PW, Fitzgerald JM.
    Thorax; 2008 Nov 15; 63(11):962-7. PubMed ID: 18621985
    [Abstract] [Full Text] [Related]

  • 16. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.
    Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B, INTENSITY study investigators.
    Eur Respir J; 2011 Oct 15; 38(4):797-803. PubMed ID: 21622587
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A.
    Int J Chron Obstruct Pulmon Dis; 2018 Oct 15; 13():3867-3877. PubMed ID: 30568438
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of once-daily indacaterol relative to alternative bronchodilators in COPD: a patient-level mixed treatment comparison.
    Cope S, Capkun-Niggli G, Gale R, Lassen C, Owen R, Ouwens MJ, Bergman G, Jansen JP.
    Value Health; 2012 May 15; 15(3):524-33. PubMed ID: 22583463
    [Abstract] [Full Text] [Related]

  • 19. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
    Oostenbrink JB, Rutten-van Mölken MP, Monz BU, FitzGerald JM.
    Value Health; 2005 May 15; 8(1):32-46. PubMed ID: 15841892
    [Abstract] [Full Text] [Related]

  • 20. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
    Hoshino M, Ohtawa J, Akitsu K.
    Pulm Pharmacol Ther; 2015 Feb 15; 30():128-33. PubMed ID: 25183687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.